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Background: Studies of the impact of type 2 diabetes on the prevalence and incidence of lower urinary tract
symptoms (LUTS) among men have provided divergent results. We sought to examine this issue using two large
and diverse cohorts.
Methods: This study used questionnaire and clinical data from two large multiethnic cohorts, the California Men’s
Health Study (CMHS) and Research Program in Genes, Environment and Health (RPGEH). Diabetes characteristics
data were derived from questionnaire and Diabetes Registry data. LUTS were measured using a standardized scale.
Socioeconomic and comorbidity data were obtained by self-report.
Multivariable logistic regression analysis was used to examine the association between baseline DM status and
prevalence and incidence of LUTS, with adjustment for potential confounding variables.
Results: We found type 2 diabetes to be associated with prevalent LUTS (odds ratio (OR) = 1.32, 95% confidence
interval (CI) 1.26, 1.38). The association was stronger among men with type 2 diabetes who were on active
pharmaceutical treatment and had it for a longer duration. No association was observed between type 2 diabetes
and new onset LUTS.
Conclusions: Type 2 diabetes increases the risk of LUTS.
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Type 2 diabetes mellitus, lower urinary tract symptoms
and benign prostatic hyperplasia are all common
disorders that affect men as they age. It is well known
that diabetes can negatively impact the bladder and is
manifested in later stages as diabetic cystopathy [1,2]. It
is less clear, however, how diabetes affects the more
common lower urinary tract symptoms (LUTS) of the
aging male [2,3].
Early studies reported that diabetes was associated
with surgery for enlarged prostate or benign prostatic
hyperplasia (BPH) [3,4]. As recently reviewed by Sarma
and Parsons [3], most studies determined that type 2
diabetes is associated with a 10-200% increase in the risk
of LUTS. However, these studies were quite variable in* Correspondence: Stephen.vandeneeden@kp.org
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distribution, and reproduction in any mediumthe way they defined LUTS; for example, the definitions
frequently included various markers of BPH, such as
medical treatment or surgery. In contrast, other studies
have not found type 2 diabetes to be associated with
LUTS or BPH [5].
The current study sought to examine the association
between type 2 diabetes and LUTS using two large
cohorts in which all participants completed a question-
naire that included a standardized assessment of LUTS,
the American Urological Association Symptom Index
(AUASI) [6].Methods
Participants of the California Men’s Health Study
(CMHS) and male subjects of the Research Program on
Genes, Environment and Health (RPGEH) cohorts
formed the study population for this study. Both cohorts
were recruited from the membership of Kaiser
Permanente in California.Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
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[7]. Briefly, CMHS baseline data were collected be-
tween 2001–2002 on 84,170 men, aged 45 to 69 years
as of 1/1/ 2001, who were members of Kaiser Permanente
Northern or Southern California regions. A second ques-
tionnaire that included the AUASI was administered to
the CMHS participants in 2007–2008. Details on the
study of LUTS within the RPGEH cohort have been previ-
ously published [8]. The RPGEH includes a cohort with
baseline data obtained in 2007–2008 on 140,139 men
who were adult members of Kaiser Permanente Northern
California for at least two years prior to the survey. Data
were available for 78,273 CMHS and 106,373 RPGEH
men after exclusions for prevalent prostate cancer or mis-
sing data. For the analysis related to new onset or incident
LUTS, only the 63,245 CMHS men who completed the
second assessment and did not have prostate cancer at
baseline or after follow-up were included. Informed con-
sent was obtained for the CMHS participants through an
information sheet that accompanied the survey and volun-
tary response. Written informed consent was obtained for
the RPGEH participants.
Questionnaire data included race/ethnicity, marital sta-
tus, birthplace, height, weight, diabetes status, comorbidity
(e.g., cardiovascular disease, hypertension, hyperlipidemia,
etc.), smoking, alcohol use and physical activity. Physical
activity was categorized as minimal, moderate or strenu-
ous based on type of activity and frequency, and consist-
ent with recommendations in a NIH consensus statement
on physical activity [9]. Body mass index (BMI) was
calculated as weight in kilograms/height in meters2 and
included in the analyses as an indicator variable with three
categories (i.e., <25, 25- < 30, 30+).
Data on LUTS were obtained using the standardized
American Urological Association Symptom Index
(AUASI) [6] with measurement at baseline for both
cohorts and at the follow-up assessment for the CMHS.
The AUASI is scored on a 0–35 scale based on seven
questions. These data were categorized as no or mild
(AUASI score of 0–7); moderate (AUASI 8–19); or se-
vere LUTS (AUASI ≥20). For some analyses, the moder-
ate and severe categories were combined. Incident LUTS
was examined only among men with no prostate cancer
at baseline or in the follow-up period, who did not
undergo BPH treatment before baseline and had an
AUASI in the no or mild category (i.e., ≤7). Men were
classified as having incident LUTS if they met any of the
following criteria: AUASI score increased from ≤7 to 8 or
more at the second assessment or underwent treatment
for BPH. The latter criterion included selected drug use
(e.g., α-blockers or 5-.alpha;-reductase inhibitors), under-
going surgery (e.g., a transurethral prostatectomy), or
other minimally invasive procedures (e.g., transurethral
microwave thermotherapy or transurethral needle ablation).For analyses that examined diabetes characteristics,
the analyses was limited to the Kaiser Permanente
Northern California (KPNC) subcohort for linkage to
the KPNC Diabetes Registry [10-13].
Statistical analysis
We first calculated the prevalence of LUTS at baseline
by dividing the number of ‘cases’ by the appropriate de-
nominator at the baseline and expressed this percentage
by age and diabetes status.
Because many conditions potentially associated with
LUTS also tend to vary by diabetes status, we analyzed
the data using logistic regression models to obtain odds
ratios for LUTS associated with type 2 diabetes adjusted
for covariates that may confound that association. We
combined moderate and severe LUTS in our analyses.
Our analysis adjusted for age, race/ethnicity, physical ac-
tivity, smoking and BMI. Other factors, such as marital
status, and alcohol use, were initially considered but
there was no evidence that they were confounding the
effect estimates and were therefore not included in re-
gression models. Factors that are known to be a conse-
quence of having type 2 diabetes, such as cardiovascular
disease and hyperlipidemia, were not included in our
primary analyses. In the combined cohort analyses we
also included an indicator variable for cohort. Statistical
tests of the regression coefficients were based on the
likelihood ratio test and Wald 95% confidence intervals
were calculated for each odds ratio.
The study was reviewed and approved by the Institu-
tional Review Boards of Kaiser Permanente Northern
and Southern California.
Results
Except for the age distribution, men were similar in both
cohorts with regard to demographic, socioeconomic and
comorbid diseases (Table 1). A total of 24,586 or 13.3%
had a history of type 2 diabetes. Approximately half of the
combined cohorts reported moderate or severe LUTS.
Overall, about 13% of the combined cohort members
reported fair or poor health. On average, the cohorts were
reasonably well educated with just over half having at least
some college level courses.
The prevalence of men with moderate or severe LUTS
increased with age in both cohorts and among men with
and without type 2 diabetes (Table 2). While the age spe-
cific prevalence was slightly higher among the RPGEH
men compared to CMHS men with or without type 2
diabetes, the prevalence was higher among men with
type 2 diabetes in all age categories in both cohorts. The
severity of LUTS was also increased with age.
In multivariable models (Table 3), men with type 2
diabetes had higher odds of moderate LUTS than men
without this condition (OR = 1.32, 95% CI 1.26-1.38).
Table 1 Selected demographic, socioeconomic, lifestyle and medical characteristics of men in the California men's
health study and research program in Genes, environment and health Cohorts
Cohort
CMHS RPGEH
N = 78,273 N = 106,373
Demographic & Social N (%) N (%)
Race
Asian 6026 7.7 11052 10.4
Black/African American 5656 7.2 10751 10.1
Hispanic 10752 13.7 9009 8.5
White 48838 62.4 72232 67.9
Other/Mixed 7001 8.9 3329 3.1
Lower urinary tract symptoms/AUASI score
0-7 37036 47.3 52424 49.3
8-19 35917 45.9 47215 44.4




40-49 12853 16.4 17655 16.6
50-59 33703 43.1 24691 23.2




Married 60314 77.1 78804 74.1
Education
High school or less 14097 18.1 17309 17.6
Some college or trade 27047 34.8 27347 27.9
School
College or more 36683 47.1 53508 54.5
Household income (per year)
<$60,000 29676 39.4 34003 34.7
$60-99,999 24640 32.7 28392 29
≥$100,000 21029 27.9 35607 36.3
At least one parent foreign born 28007 35.8 38968 36.6
Medical Co-morbidities
Fair or poor general health 9684 12.4 15251 14.3
Current or past diabetes 9579 12.2 15007 14.1
Current or past hypertension 28502 36.4 33537 31.5
Cardiovascular disease 13097 16.7 12773 12
Erectile dysfunction 22863 29.2 39646 37.3
Health or behavior characteristics
Smoking status
Never smoker 32940 43.4 60570 56.9
Former smoker 34768 45.8 36919 34.7
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Table 1 Selected demographic, socioeconomic, lifestyle and medical characteristics of men in the California men's
health study and research program in Genes, environment and health Cohorts (Continued)
Current smoker 8275 10.9 8884 8.4
ETOH > = 5 drinks/week 6429 8.2 8455 8
Body mass Index (mean, SD) 27.9 4.8 27.5 5
Vegetables or fruit per week
3-4 times 10450 13.4 21006 19.8
5 or more times 58457 74.7 74201 69.8
Physical activity (moderate or vigorous) per week
3-4 times 21310 27.2 32861 30.9
5 or more times 13961 17.8 22269 20.9
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by treatment status, use of oral antihyperglycemia agents
or insulin was associated with an increased odds of
LUTS than men without type 2 diabetes. Longer dur-
ation of type 2 diabetes was associated with an increased
odds of LUTS, although men with shorter duration of
type 2 diabetes had a higher odds relative to men with-
out type 2 diabetes. These trends were also apparent
when analyses were restricted to the men with type 2
diabetes (data not shown).
Finally, in the CMHS cohort, type 2 diabetes at base-
line questionnaire was associated with a 7% increased
odds of LUTS progression (OR = 1.07, 95% CI 0.95, 1.02),
as determined by increasing AUASI score or having re-
ceived treatment for BPH/LUTS after baseline (Table 4).
Again, the confidence interval included the null and there-
fore the data are consistent with no association between
DM and LUTS incidence. We did not see an increase in
the odds of LUTS with markers of disease severity such as
medication use or duration.
Discussion
We found clear associations between type 2 diabetes and
prevalent lower urinary tract symptoms. Men with type
2 diabetes reported higher AUASI scores in each age
group in both cohorts studied. Men with type 2 diabetes
were 32% more likely to report LUTS compared to men
without type 2 diabetes. The association was stronger with
indicators of poorer type 2 diabetes status (e.g., more in-
tensive medical management or duration). In contrast, we
found that type 2 diabetes had little if any impact on the
risk of developing new LUTS.
The earliest studies of diabetes and LUTS found an as-
sociation between diabetes and surgery for BPH [4,14,15].
However, surgery for BPH as an endpoint represents a
pathway that includes severity of LUTS, the presence of
comorbidities that represent surgical contraindications,
healthcare access and other concerns. More recent studies
have used a mixed definition of BPH that included
BPH surgery, symptoms or results of a digital rectalexam [16-19]. These studies have all found associations
that consistently point to diabetes affecting voiding
function. However, they have not clearly sorted out the
underlying mechanism – i.e., dysfunction due to an in-
crease in obstruction secondary to BPH or bladder dys-
function secondary to microvascular and neuropathic
effects related to diabetes. However, the evidence of dia-
betes effect on obstruction is mixed and primarily limited
to examination of prostate volume. Sarma et al. [20] found
no association between diabetes and prostate volume.
Interestingly, they reported a stronger association for irri-
tative LUTS compared to obstructive LUTS. Also relevant
to this discussion, Burke et al. [21], using the Olmsted
County Study (OCS) data, reported that diabetes was
associated with the progression of LUTS, but was not
associated with an increase in prostate volume or PSA
level. In contrast to our study, Sarma et al. [22], using the
same OCS population and the Flint Men’s Health Study,
found no association between diabetes medication treat-
ment and progression of LUTS. They did report that the
association between diabetes and LUTS seemed to be
stronger for irritative symptoms compared to obstructive
symptoms. However, the study was limited in that only
101 of the men had diabetes in their analysis. However,
other, smaller studies, suggest that diabetes may be related
to prostate growth [23]. While another larger study
reported fasting glucose to be associated with increased
prostate volume, there was an irregular dose–response pat-
tern across quartiles of fasting glucose which limits the in-
terpretation of those data [18]. Nonetheless, these data
taken together suggest a bigger impact of diabetes on
voiding symptoms unrelated to obstruction, such as the
bladder.
It may be that diabetes also adversely affects voiding in
combination with other health issues. Kupelian et al.
reported an association between metabolic syndrome
and LUTS [24]. However, data from the Third National
Health and Nutrition Examination Survey (NHANES III)
did not find diabetes or most markers of glucose metabol-
ism (or metabolic syndrome) associated with selected
Table 2 Baseline prevalence of diabetes* and LUTS† by age by cohort
Age (years) at baseline
<45 45-49 50-59 60-69 70-79 Total
n (%) n (%) n (%) n (%) n (%) n (%)
CMHS - DM 908 7.1% 3661 10.9% 5010 15.8% 9579 12.2%
CMHS - No DM 11945 92.9% 30042 89.1% 26707 84.2% 68694 87.8%
12853 33703 31717 78273
RPGEH - DM 887 5.91 833 8.0% 3099 12.6% 5030 18.6% 5156 21.8% 15005 14.1%
RPGEH - Not DM 19683 21.54 9599 92.0% 21589 87.4% 22013 81.4% 18476 78.2% 91360 85.9%
LUTS score‡ Diabetes
0-7 514 57.9% 904 51.9% 2923 43.2% 3513 35.0% 1465 28.4% 9319 37.9%
8-19 339 38.2% 741 42.6% 3374 49.9% 5405 53.8% 2988 58.0% 12847 52.3%
≥20 34 3.8% 96 5.5% 463 6.8% 1122 11.2% 703 13.6% 2418 9.8%
LUTS score‡ Non-Diabetes
0-7 14059 71.4% 13185 61.2% 27075 52.4% 20153 41.4% 5667 30.7% 80139 50.1%
8-19 5369 27.3% 7769 36.1% 22064 42.7% 24430 50.1% 10648 57.6% 70280 43.9%
≥20 255 1.3% 590 2.7% 2492 4.8% 4137 8.5% 2161 11.7% 9635 6.0%
* From baseline questionnaire data; Diabetes = yes response to having been told by physician had diabetes.
† AUASI score of 8 or more.
‡ Both cohort are combined.
Kaiser Permanente California.
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not include a standardized assessment of LUTS [5]. In this
study, however, glycosylated hemoglobin was associated
with increased prevalence of lower urinary tract
symptoms. A study from Austria also failed to find meta-
bolic syndrome (as well as fasting glucose) to be associated
with LUTS [25]. In a follow-up of men with type 1 dia-
betes who were participants in the DCCT/EDIC study, no
association between glycosylated hemoglobin (or other
markers of disease severity) and LUTS was observed [26].Table 3 Risk of prevalent lower urinary tract symptoms
by diabetes characteristics, CMHS and RPGEH Cohorts,
Kaiser Permanente
LUTS †
OR * 95% CI
Diabetes No 1.0 (ref) ref ref
Yes 1.32 1.26 1.38
Treatment Not DM 1.0 (ref) ref ref
None 1.13 0.97 1.32
Oral medication 1.40 1.29 1.51
Insulin 1.28 1.10 1.48
Duration Not DM 1.0 (ref) ref ref
<5 years 1.28 1.18 1.40
≥5 years 1.38 1.27 1.51
* Adjusted for age, race/ethnicity, physical activity, smoking, and body
mass index.
† AUASI score of 8 or more.The relationship between diabetes and progression of
LUTS is complicated by possibly multiple changes over
time. If diabetes does not increase the prostate volume it
may result in a leveling off LUTS in men where obstruc-
tion is contributing. However, if diabetes impacts the
bladder through vascular and neuropathic mechanisms,
it may increase LUTS. Our data on progression do not
point to a clear explanation as to which of these
mechanisms are operating. The lack of an association
with progression in our data may be due to issuesTable 4 Risk of new onset lower urinary tract symptoms
by diabetes characteristics, CMHS Cohort, Kaiser
Permanente
LUTS †
OR * 95% CI
Diabetes No 1.0 (ref) ref ref
Yes 1.07 0.95 1.2
Treatment‡ Not DM 1.0 (ref) ref ref
None 1.17 1.03 1.34
Oral medication 0.87 0.69 1.09
Insulin 0.91 0.61 1.3
Duration‡ Not DM 1.0 (ref) ref ref
<5 years 1.07 0.92 1.25
≥5 years 1.05 0.88 1.25
* Adjusted for age, race/ethnicity, physical activity, smoking, and body
mass index.
† AUASI score of 8 or more.
‡ CMHS cohort only.
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short follow-up.
Conclusions
We found a clear association between diabetes and preva-
lent LUTS but no association with new onset LUTS.
Abbreviations
LUTS: Lower urinary tract symptoms; BPH: Benign prostatic hyperplasia;
AUASI: American Urological Association Symptom Index; CMHS: California
Men’s Health Study; RPGEH: Research Program on Genes, Environment and
Health; BMI: Body mass index; KPNC: Kaiser Permanente Northern California.
Competing interests
Stephen Van Den Eeden has received salary support from research grants
from the National Institutes of Health, GlaxoSmithKline and Takada for
studies unrelated to this paper. Assiamira Ferrara has received salary support
or research grants from the National Institutes of Health, GlaxoSmithKline,
sanofi-aventis and Takada for studies unrelated to this paper. Steven
Jacobsen has received research support from the National Institutes of
Health and Merck for studies unrelated to this paper. Charles Quesenberry
has received salary support or research grants from the National Institutes of
Health, GlaxoSmithKline, sanofi-aventis and Takada for studies unrelated to
this paper. Jun Shan declares there are no competing interests. Virginia
Quinn declares there are no competing interests. Reina Haque declares there
are no competing interests.
Authors’ contributions
SKV designed, helped acquire the data, conducted the analysis, drafted the
manuscript and gave final approval to be published. AF helped acquire the
data, critically revised the manuscript and gave final approval to be
published. JS conducted the analysis, critically revised the manuscript and
gave final approval to be published. SJJ critically revised the manuscript and
gave final approval to be published. VQ helped acquire the data, critically
revised the manuscript and gave final approval to be published. RH critically
revised the manuscript and gave final approval to be published. CPQ helped
acquire the data, conduct the analysis, critically revised the manuscript and
gave final approval to be published. All authors read and approved the final
manuscript.
Authors’ information
Dr. Van Den Eeden is a Research Scientist at the Division of Research at
Kaiser Permanente Northern California, a Professor in the Department of
Urology at UCSF and a Lecturer in Epidemiology at Stanford University.
Acknowledgement
Original cohort funding obtained from the California Cancer Research
Program, The Wayne and Gladys Valley Foundation, and the Kaiser
Permanente Community Benefits Program. Study funding from the National
Institute of Diabetes, Digestive Diseases and Kidney through the Urologic
Diseases in America Project at UCLA. We thank the men who have
generously participated in California Men’s Health Study and the Research
Program in Genes, Environment and Health. Dr. Van Den Eeden is the
guarantor of this work and, as such, had full access to all of the data in the
study and takes responsibility for the integrity of the data and the accuracy
of the data analysis.
Author details
1Division of Research, Kaiser Permanente Northern California, 2000 Broadway,
Oakland, CA 94612, USA. 2Research and Evaluation, Kaiser Permanente
Southern California, Pasadena, CA, USA.
Received: 29 September 2012 Accepted: 8 February 2013
Published: 20 February 2013
References
1. Brown JB, Wessells H, Chancellor MB, Stamm WE, Stapleton AE, Steers WD,
Van Den Eeden SK, McVary KT: Urologic outcomes in diabetes. Diabetes
Care 2005, 28(1):177–185.2. Sasaki K, Yoshimura N, Chancellor MB: Implications of diabetes mellitus in
urology. UrolClinNorth Am 2003, 30(1):1–12.
3. Sarma AV, Kellogg PJ: Diabetes and benign prostatic hyperplasia:
emerging clinical connections. CurrUrolRep 2009, 10(4):267–275.
4. Sidney S, Quesenberry CP Jr, Sadler MC, Guess HA, Lydick EG, Cattolica EV:
Incidence of surgically treated benign prostatic hypertrophy and of
prostate cancer among blacks and whites in a prepaid health care plan.
Am J Epidemiol 1991, 134:825–829.
5. Rohrmann S, Smit E, Giovannucci E, Platz EA: Association between markers
of the metabolic syndrome and lower urinary tract symptoms in the
Third National Health and Nutrition Examination Survey (NHANES III).
IntJObes(Lond) 2005, 29(3):310–316.
6. Barry MJ, Fowler FJ Jr, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust
WK, Cockett AT: The American Urological association Symptom index for
benign prostatic Hyperplasia. The measurement committee of the
American Urological association. JUrol 1992, 148(5):1549–1557.
7. Enger SM, Van Den Eeden SK, Sternfeld B, Loo RK, Quesenberry CP Jr,
Rowell S, Sadler MC, Schaffer DM, Habel LA, Caan BJ: California Men's
Health Study (CMHS): a multiethnic cohort in a managed care setting.
BMCPublic Health 2006, 6:172.
8. Van Den Eeden SK, Shan J, Jacobsen SJ, Aaronsen D, Haque R, Quinn VP,
Quesenberry CP Jr: Evaluating racial/ethnic disparities in lower urinary
tract symptoms in men. J Urol 2012, 187(1):185–189.
9. Health NCDPPAC: Physical activity and cardiovascular health. NIH
Consensus Development Panel on Physical Activity and Cardiovascular
Health. JAMA 1996, 276(3):241–246.
10. Ferrara A, Karter AJ, Ackerson LM, Liu JY, Selby JV: Hormone replacement
therapy is associated with better glycemic control in women with type 2
diabetes: The Northern California Kaiser Permanente Diabetes Registry.
Diabetes Care 2001, 24(7):1144–1150.
11. Karter AJ, Ackerson LM, Darbinian JA, D'Agostino RB Jr, Ferrara A, Liu J,
Selby JV: Self-monitoring of blood glucose levels and glycemic control:
the Northern California Kaiser Permanente Diabetes registry. AmJMed
2001, 111(1):1–9.
12. Karter AJ, Ferrara A, Liu JY, Moffet HH, Ackerson LM, Selby JV: Ethnic
disparities in diabetic complications in an insured population. JAMA
2002, 287(19):2519–2527.
13. Selby JV, Ettinger B, Swain BE, Brown JB: First 20 months' experience with
use of metformin for type 2 diabetes in a large health maintenance
organization. Diabetes Care 1999, 22(1):38–44.
14. Bourke JB, Griffin JP: Diabetes mellitus in patients with benign prostatic
hyperplasia. Br MedJ 1968, 4(629):492–493.
15. Glynn RJ, Campion EW, Bouchard GR, Silbert JE: The development of
benign prostatic hyperplasia among volunteers in the Normative Aging
Study. AmJEpidemiol 1985, 121(1):78–90.
16. Kristal AR, Arnold KB, Schenk JM, Neuhouser ML, Weiss N, Goodman P,
Antvelink CM, Penson DF, Thompson IM: Race/ethnicity, obesity, health
related behaviors and the risk of symptomatic benign prostatic
hyperplasia: results from the prostate cancer prevention trial. JUrol 2007,
177(4):1395–1400.
17. Meigs JB, Mohr B, Barry MJ, Collins MM, McKinlay JB: Risk factors for clinical
benign prostatic hyperplasia in a community-based population of
healthy aging men. JClinEpidemiol 2001, 54(9):935–944.
18. Parsons JK, Carter HB, Partin AW, Windham BG, Metter EJ, Ferrucci L, Landis
P, Platz EA: Metabolic factors associated with benign prostatic
hyperplasia. JClinEndocrinolMetab 2006, 91(7):2562–2568.
19. Platz EA, Kawachi I, Rimm EB, Willett WC, Giovannucci E: Race, ethnicity
and benign prostatic hyperplasia in the health professionals follow-up
study. JUrol 2000, 163(2):490–495.
20. Sarma AV, Burke JP, Jacobson DJ, McGree ME, St Sauver J, Girman CJ, Lieber
MM, Herman W, Macoska J, Montie JE, et al: Associations between
diabetes and clinical markers of benign prostatic hyperplasia among
community-dwelling Black and White men. Diabetes Care 2008,
31(3):476–482.
21. Burke JP, Jacobson DJ, McGree ME, Roberts RO, Girman CJ, Lieber MM,
Jacobsen SJ: Diabetes and benign prostatic hyperplasia progression in
Olmsted County, Minnesota. Urology 2006, 67(1):22–25.
22. Sarma AV, St Sauver JL, Hollingsworth JM, Jacobson DJ, McGree ME, Dunn
RL, Lieber MM, Jacobsen SJ: Diabetes treatment and progression of
benign prostatic hyperplasia in community-dwelling black and white
men. Urology 2012, 79(1):102–108.
Van Den Eeden et al. BMC Urology 2013, 13:12 Page 7 of 7
http://www.biomedcentral.com/1471-2490/13/1223. Hammarsten J, Hogstedt B: Clinical, anthropometric, metabolic and
insulin profile of men with fast annual growth rates of benign prostatic
hyperplasia. Blood Press 1999, 8(1):29–36.
24. Kupelian V, McVary KT, Kaplan SA, Hall SA, Link CL, Aiyer LP, Mollon P,
Tamimi N, Rosen RC, McKinlay JB: Association of lower urinary tract
symptoms and the metabolic syndrome: results from the Boston Area
Community Health Survey. JUrol 2009, 182(2):616–624.
25. Temml C, Obermayr R, Marszalek M, Rauchenwald M, Madersbacher S,
Ponholzer A: Are Lower Urinary Tract Symptoms Influenced by Metabolic
Syndrome? Urology 2009, 73(3):544–8.
26. van den Eeden SK, Sarma AV, Rutledge BN, Cleary PA, Kusek JW, Nyberg LM,
McVary KT, Wessells H: Effect of intensive glycemic control and diabetes
complications on lower urinary tract symptoms in men with type 1
diabetes: Diabetes Control and Complications Trial/Epidemiology of
Diabetes Interventions and Complications (DCCT/EDIC) study. Diabetes
Care 2009, 32(4):664–670.
doi:10.1186/1471-2490-13-12
Cite this article as: Van Den Eeden et al.: Impact of type 2 diabetes on
lower urinary tract symptoms in men: a cohort study. BMC Urology 2013
13:12.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
